Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting 2024
November 18, 2024 18:00 ET | Source: Pliant Therapeutics, Inc. INTEGRIS-PSC featured…
Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
November 16, 2024 02:53 ET | Source: Junshi Biosciences SHANGHAI, Nov. 16,…
AlveoGene Receives Rare Pediatric Disease Designation (RPDD)from FDA for AVG-002, its Novel, Inhaled Gene Therapy forLethal Neonatal Surfactant Protein B (SP-B) Deficiency
Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress…
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
November 14, 2024 07:01 ET | Source: Invivyd The New England Journal…
Sparian Biosciences Announces Results from the Phase 1 Clinical Trial of First in Class Novel Arylepoxamide Receptor (AEAr) Agonist Analgesic SBS-1000
SBS-1000 was shown to be safe and well tolerated in healthy volunteers…
French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance
STRASBOURG, France, Nov. 11, 2024 (GLOBE NEWSWIRE) -- AdipoPharma, a biotech company…
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on…
Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement
November 08, 2024 16:15 ET | Source: Bionomics Ltd ADELAIDE, Australia and CAMBRIDGE,…
HarperCollins India Announces the publication of ‘The Homecoming’ by Preeti Shenoy
Paperback |Fiction| INR 399Available now on pre-order | Releasing 28 November 2024…
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
Company announced completed Phase 1 enrollment for SAB-142 with no observation of…